Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1975707 | 1.00 | MAPT (0.40) | MAPTHTTSMN1; SMN2MIFTSHR | |
| SCHEMBL16201772 | 0.85 | TSHR (0.41) | MAPTHTTSMN1; SMN2TSHRCYP2C19 | |
| SCHEMBL16201781 | 0.85 | TSHR (0.41) | MAPTHTTSMN1; SMN2TSHRCYP2C19 | |
| SCHEMBL6822889 | 0.81 | FAAH (0.44) | MAPT | |
| SCHEMBL20185592 | 0.80 | SMN1; SMN2 (0.43) | HTTSMN1; SMN2MIFCYP2C19LTA4H | |
| SCHEMBL8301341 | 0.77 | LTA4H (0.46) | MIFLTA4HTDP1KMT2ANPC1 | |
| SCHEMBL1975297 | 0.76 | CA1 (0.46) | HTTSMN1; SMN2TSHRTEAD3CYP2C19 | |
| SCHEMBL1975300 | 0.76 | CA1 (0.46) | HTTSMN1; SMN2TSHRTEAD3CYP2C19 | |
| SCHEMBL24257609 | 0.76 | MAPT (0.40) | MAPTHTTSMN1; SMN2TSHRTEAD3 | |
| SCHEMBL2913807 | 0.76 | MMP3 (0.48) | MIFTSHRLTA4HTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889894-B2 | Compounds for use in therapy | BANGOR UNIVERSITY (GB) | 2014-11-18 | — | — | US | disclosed |
| US-8728515-B2 | Adjuvants for use in vaccination | BANGOR UNIVERSITY (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2620158-A1 | Adjuvants for use in vaccination | Bangor University (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20110150981-A1 | Compounds for Use in Therapy | BANGOR UNIVERSITY (GB) | 2011-06-23 | — | — | US | disclosed |
| US-20110142916-A1 | Adjuvants for Use in Vaccination | BANGOR UNIVERSITY (GB) | 2011-06-16 | — | — | US | disclosed |
| EP-2278995-A2 | COMPOUNDS FOR USE IN THERAPY | Bangor University (GB) | 2011-02-02 | — | — | EP | disclosed |
| EP-2278996-A1 | ADJUVANTS FOR USE IN VACCINATION | Bangor University (GB) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009130506-A2 | COMPOUNDS FOR USE IN THERAPY | BANGOR UNIVERSITY (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130508-A1 | ADJUVANTS FOR USE IN VACCINATION | BANGOR UNIVERSITY (GB) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142916-A1 | Adjuvants for Use in Vaccination | NR1H3, NR1H2, INTS6 | MAPT 4766/4885HTT 2273/4885SMN1; SMN2 4082/4885 |
| US-20110150981-A1 | Compounds for Use in Therapy | CD4, MSR1, TST | MAPT 4322/4885HTT 1950/4885SMN1; SMN2 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.